Gastric carcinoma: Clinical, pathogenic and molecular aspects

QJM: An International Journal of Medicine

Volumn 90, Issue 12, 1997, Pages 735-749

  Blok, P ^a   Craanen, M E ^b   Offerhaus, G J A ^c   Tytgat, G N J ^c  

^a MEDICAL CENTER HAAGLANDEN   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL FEATURE; HELICOBACTER PYLORI; HUMAN; MOLECULAR BIOLOGY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; STOMACH CARCINOGENESIS; STOMACH CARCINOMA;

EID: 0031442197     PISSN: 00335622     EISSN: None     Source Type: Journal    
DOI: 10.1093/qjmed/90.12.735     Document Type: Review

References (261)

1. Devesa SS, Silverman DT. Cancer incidence and mortality trends in the United States: 1935-74. J Natl Cancer Inst 1978; 60:545-71.
2. Pollack ES, Horm JW. Trends in cancer incidence and mortality in the United States, 1969-76. J Natl Cancer Inst 1980; 64:1091-103.
3. Viste A, Soreide O, Glattre E. Stomach cancer: major trends in incidence during introduction of gastroscopy service in Norway. Scand J Gastroenterol 1985; 20:99-108.
4. DeCarli A, La Vecchia C, Cislaghi C, Mezzanotte G, Marubini E. Descriptive epidemiology of gastric cancer in Italy. Cancer 1986; 58:2560-9.
5. Breaux JR, Bringaze W, Chappuis C, Cohn I. Adenocarcinoma of the stomach: A review of 35 years and 1 710 cases. World J Surg 1990; 14:580-6.
6. Nobrega FT, Sedlack JD, Sedlack RE, Dockerty MB, Ilstrup DM, Kurland LT. A decline in carcinoma of the stomach. A diagnostic artifact? Mayo Clin Proc 1983; 58:255-60.
7. Maartmann-Moe H, Hartveit F. On the reputed decline in gastric carcinoma: necropsy study from western Norway. Br Med J 1985; 290:103-5.
8. Centraal Bureau voor de Statistiek. Vademecum gezondheidsstatistiek Nederland. 's Gravenhage, SDU Uit geverij, 1989.
9. Lundegårdh G, Adami HO, Malker B. Gastric cancer survival in Sweden. Lack of improvement in 19 years. Ann Surg 1986; 204:546-51.
10. Allum WH, Powell DJ, McConkey CC, Fielding JWL. Gastric cancer: a 25-year review. Br J Surg 1989; 76:535-40.
11. Boddie AW, McBride CM, Balch CM. Gastric cancer. Am J Surg 1989; 157:595-606.
12. Craven JL. Gastric cancer. Curr Opin Gastroenterol 1990; ??:928-34.
13. Murakami T. Pathomorphological diagnosis. Definition and gross classification of early gastric cancer. In Murakami T, ed. Early gastric cancer. Gann monograph on cancer research 11. Tokyo, University of Tokyo Press 1971:53-5.
14. Green PHR, O'Toole KM, Slonim D, Wang T. Increasing incidence and excellent survival of patients with early gastric cancer : experience in a United States medical center. Am J Med 1988; 85:658-61.
15. Bringaze WL, Chappuis CW, Cohn I, Correa P. Early gastric cancer: 21 year experience. Ann Surg 1986; 204:103-7.
16. Green PHR, O'Toole KM, Weinberg LM, Goldfarb JP. Early gastric cancer. Gastroenterology 1981; 81:247-56.
17. Carter KJ, Schaffer HA, Ritchie WP. Early gastric cancer. Ann Surg 1984; 199:604-9.
18. O'Brien MJ, Burakoff R, Robbins EA, Golding RM, Zamcheck N, Gottlieb LS. Early gastric cancer, clinicopathologic study. Am J Med 1985; 78:195-202.
19. Carter KJ, Schaffer HA, Ritchie WP. Early gastric cancer. Ann Surg 1984; 199:604-9.
20. Ito Y, Blackstone MO, Riddell RH, Kirsner JB. The endoscopic diagnosis of early gastric cancer. Gastrointest Endosc 1979; 25:96-101.
21. Grigioni WF, Alampi G, Bondi A, Biasco G, Santini D, Miglioli M. Retrospective studies of early gastric cancer in a high incidence area of Italy. Histopathology 1980; 4:533-45.
22. Evans DMD, Craven JL, Murphy F, Cleary BK. Comparison of 'early gastric cancer' in Britain and Japan. Gut 1978; 19:1-9.
23. Ohman U, Emas S, Rubio C. Relation between early and advanced gastric cancer. Am J Surg 1980; 140:351-5.
24. Lawrence M, Shiu MH. Early gastric cancer. Twenty eight year experience. Ann Surg 1991; 213:327-34.
25. Op den Orth JO, Ploem S. The standard biphasic-contrast gastric series. Radiology 1977; 122:530-2.
26. Craanen ME, Dekker W, Ferwerda J, Blok P, Tytgat GNJ. Early gastric cancer: a clinicopathologic study. J Clin Gastroenterol 1991; 13:274-83.
27. Miller G, Froelicher P, Kaufmann M, Maurer W. Ten years endoscopic diagnosis of early gastric cancer in Europe. J Clin Res Clin Oncol 1979; 93: 99-107.
28. Antonioli DA, Goldman H. Changes in the location and type of gastric adenocarcinoma. Cancer 1982; 50:775-81.
29. Golematis B, Tzardis P, Hatzikostas P, Papadimitriou K, Haritopoulos N. Changing patterns of distribution of carcinoma of the stomach. Br J Surg 1990; 77:63-4.
30. Paterson IM, Easton DF, Corbishley CM, Gazet JC. Changing distribution of adenocarcinoma of the stomach. Br J Surg 1987; 74:481-2.
31. Craanen ME, Dekker W, Blok P, Ferwerda J, Tytgat GNJ. Time trends in gastric carcinoma: changing patterns of type and location. Am J Gastroenterol 1992; 87:572-9.
32. Meyers WC, Damiano RJ, Postlethwait RW, Rotolo FS. Adenocarcinoma of the stomach. Changing patterns over the last 4 decades. Ann Surg 1987; 205:1-8.
33. Husemann B. Cardia carcinoma considered as a distinct clinical entity. Br J Surg 1989; 76:136-9.
34. Yamada Y, Kato Y. Greater tendency for submucosal invasion in fundic area gastric carcinomas than those arising in the pyloric area. Cancer 1989; 63:1757-60.
35. Munoz N, Connelly R. Time trends of intestinal and diffuse types of gastric cancer in the United States. Int J Cancer 1971; 8:158-64.
36. Amorosi A, Bianchi S, Buiatti E, Cipriani F, Palli D, Zampi G. Gastric cancer in a high-risk area in Italy. Histopathologic patterns according to Lauren's classification. Cancer 1988; 62:2191-6.
37. Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. Acta Pathol Microbiol Scand 1965; 64:31-49.
38. Correa P. A human model of gastric carcinogenesis. Cancer Res 1988; 48:1319-26.
39. Hirota T, Itabashi M, Suzuki K, Yoshida S. Clinicopathologic study of minute and small early gastric cancer. Pathol Annu 1980; 15:1-19.
40. Yamashina M. A variant of early gastric carcinoma. Cancer 1986; 58:1333-9.
41. Iishi H, Yamamoto R, Tatsuta M, Okuda S. Evaluation of fine needle aspiration biopsy under direct vision gastrofiberscopy in diagnosis of diffusely infiltrative carcinoma of the stomach. Cancer 1986; 57:1365-9.
42. Andriulli A, Recchia S, De Angelis C, et al. Endoscopic ultrasonographic evaluation of patients with biopsy negative gastric linitis plastica. Gastrointest Endosc 1990; 36:611-15.
43. Hermanek P. Prognostic factors in stomach cancer surgery. Eur J Surg Oncol 1986; 12:241-6.
44. Gall FP, Hermanek P. New aspects in the surgical treatment of gastric carcinoma. A comparative study of 1636 patients operated between 1969-1982. Eur J Surg Oncol 1985; 1:219-25.
45. Bozzetti F, Bonfanti G, Bufalino R, et al. Adequacy of margins of resection in gastrectomy for cancer. Ann Surg 1982; 196:685-90.
46. Goldsmith HS, Akiyama H. A comparative study of Japanese and American gastric dimensions. Ann Surg 1978; 188:711-15.
47. Koga S, Kaibara N, Iitsuka Y, Kudo H, Kimura A, Hiraoka H. Prognostic significance of intraperitoneal free cancer cells in gastric cancer patients. J Cancer Res Clin Oncol 1984; 108:236-8.
48. Boku T, Nakane Y, Minoura T, et al. Prognostic significance of serosal invasion and free intraperitoneal cancer cells in gastric cancer. Br J Surg 1990; 77:436-9.
49. Davessar K, Pezzulo JC, Kessimian N, Hale JH, Jauregui HO. Gastric adenocarcinoma: Prognostic significance of several pathologic parameters and histologic classification. Hum Pathol 1990; 21:325-32.
50. Ribeiro MM, Sarmento JA, Simoes MAS, Bastos J. Prognostic significance of Lauren and Ming classifications and other pathologic parameters in gastric carcinoma. Cancer 1981; 47:780-4.
51. Correa P, Cuello C, Duque E, et al. Gastric cancer in Columbia.III. Natural history of precursor lesions. J Natl Cancer Instl 1976; 57:1027-35.
52. Correa P, Cuello C, Duque E. Carcinoma and intestinal metaplasia of the stomach in Columbian migrants. J Natl Cancer Inst 1970; 44:297-306.
53. Stemmermann GN, Ishidate T, Samloff IM, et al. Intestinal metaplasia of the stomach in Hawaii and Japan: A study of its relation to serum pepsinogen I, gastrin and parietal cell antibodies. Am J Dig Dis 1978; 23:815-20.
54. Sipponen P, Kekki M, Haapakoski J, Ihamäki T, Siurala M. Gastric cancer risk in chronic atrophic gastritis: statistical calculations of cross-sectional data. Int J Cancer 1985; 35:173-7.
55. Ihamäki T, Sipponen P, Varis K, Kekki M, Siurala M. Characteristics of gastric mucosa which precede occurrence of gastric malignancy: Results of long-term follow-up of three family samples. Scand J Gastroenterol 1991; 26(suppl 186):16-23.
56. Sipponen P, Kekki M, Siurala M. Atrophic gastritis and intestinal metaplasia in gastric carcinoma. Comparison with a representative population sample. Cancer 1983; 52:1062-8.
57. Sipponen P, Kekki M, Siurala M. Age-related trends of gastritis and intestinal metaplasia in gastric carcinoma patients and in controls representing the population at large. Br J Cancer 1984; 49:521-30.
58. Ming SC, Goldman H, Freiman DG. Intestinal metaplasia and histogenesis of carcinoma in human stomach. Light and electron microscopic study. Cancer 1969; 20:1418-29.
59. Nevalainen TJ, Järvi OH. Ultrastructure of intestinal and diffuse type gastric carcinoma. J Path 1977; 122:129-36.
60. Meister H, Holubarsch CH, Haferkamp O, Schlag P. Gastritis, intestinal metaplasia and dysplasia versus benign ulcer in stomach and duodenum and gastric carcinoma: A histotopographicical study. Pathol Res Pract 1979; 164:256-69.
61. Craanen ME, Blok P, Dekker W, Ferwerda J, Tytgat GNJ. Early gastric cancer and intestinal metaplasia. Eur J Gastroenterol Hepatol 1991; 3:935-40.
62. Stemmermann GN, Hayashi T. Intestinal metaplasia of the gastric mucosa: a gross and microscopic study of its distribution in various disease states. J Natl Cancer Inst 1968; 41:627-34.
63. Hattori T. Development of adenocarcinoma in the stomach. Cancer 1986; 57:1528-34.
64. Jass JR, Filipe MI. A variant of intestinal metaplasia associated with gastric carcinoma: a histochemical study. Histopathology 1979; 3:191-9.
65. Jass JR. Role of intestinal metaplasia in the histogenesis of gastric carcinoma. J Clin Pathol 1980; 33:801-10.
66. st ed. Edinburgh, Churchill Livingstone, 1989:71.
67. Heilmann KL, Höpker WW. Loss of differentiation in intestinal metaplasia in cancerous stomachs. A comparative morphologic study. Pathol Res Pract 1979; 164:249-58.
68. Segura DI, Montera C. Histochemical characterization of different types of intestinal metaplasia in gastric mucosa. Cancer 1983; 52:498-503.
69. Craanen ME, Blok P, Dekker W, Ferwerda J, Tytgat GNJ. Prevalence of subtypes of intestinal metaplasia in gastric antral mucosa. Dig Dis Sci 1991; 36:1529-36.
70. Jass JR, Filipe MI. The mucin profiles of normal gastric mucosa, intestinal metaplasia and its variants and gastric carcinoma. Histochem J 1981; 13:931-9.
71. Jass JR, Filipe MI. Sulphomucins and precancerous lesions of the human stomach. Histopathology 1980; 4:271-9.
72. Day DW, Morson BC. Gastric cancer. In: Anthony PP, Woolf N, eds. Recent advances in Histopathology. Edinburgh, Churchill Livingstone, 1978:159-78.
73. Sipponen P, Seppälä K, Varis K, et al. Intestinal metaplasia with colonic type sulphomucins in the gastric mucosa; its association with gastric carcinoma. Acta Pathol Microbiol Scand 1980; 88:217-24.
74. Filipe MI, Munoz N, Matko I, Pompe-Kim V, Jutersek A, Teuchmann S, et al. Intestinal metaplasia types and the risk of gastric cancer. Int J Cancer 1994; 57:324-9.
75. Rokkas T, Filipe MI, Sladen GE. Detection of an increased incidence of early gastric cancer in patients with intestinal metaplasia type III who are closely followed up. Gut 1991; 32:1110-13.
76. Ectors N, Dixon MF. The prognostic value of sulphomucin positive intestinal metaplasia in the development of gastric cancer. Histopathology 1986; 10:1271-7.
77. Ramesar KC, Sanders DS, Hopwood D. Limited value of type III intestinal metaplasia in predicting risk of gastric carcinoma. J Clin Pathol 1987; 40:1287-90.
78. Hill AB. The environment and disease. Association and causation. Proc Roy Soc Med 1965; 58:295-300.
79. Correa P. Is gastric carcinoma an infectious disease? N Engl J Med 1991; 325:1170-1.
80. Craanen ME, Dekker W, Blok P, Ferwerda J, Tytgat GNJ. Intestinal metaplasia and Helicobacter pylori: an endoscopic-bioptic study of the gastric antrum. Gut 1992; 33:16-20.
81. Rugge M, Mario di F, Cassaro M, et al. Pathology of the gastric antrum and body associated with Helicobacter pylori infection in non-ulcerous patients: is the bacterium a promoter of intestinal metaplasia? Histopathology 1993; 22:9-15.
82. Guarner J, Mohar A, Parsonnet J, Halperin D. The association of Helicobacter pylori with gastric cancer and preneoplastic lesions in Chiapas, Mexico. Cancer 1993; 71:297-301.
83. Parsonnet J, Vandersteen DP, Goates J, Sibley RK, Pritikin J, Chang Y. Helicobacter pylori in intestinal-and diffuse-type gastric adenocarcinomas. J Natl Cancer Inst 1991; 83:640-3.
84. Loffeld RJLF, Willems I, Flendrig JA, Arends JW. Helicobacter pylori and gastric carcinoma. Histopathology 1990; 17:537-41.
85. Wee A, Kang JY, Teh M. Helicobacter pylori and gastric cancer: correlation with gastritis, intestinal metaplasia, and tumour histology. Gut 1992; 33:1029-32.
86. Sipponen P, Kosunen TU, Valle J, Riihela M, Seppälä K. Helicobacter pylori infection and chronic gastritis in gastric cancer. J Clin Pathol 1992; 45: 319-23.
87. Craanen ME, Blok P, Dekker W, Tytgat GNJ. Helicobacter pylori and early gastric cancer. Gut 1994; 35:1372-4.
88. Kuipers EJ. The interrelation between Helicobacter pylori, chronic gastritis and gastric cancer. PhD Thesis. Free University Amsterdam, 1995.
89. Forman D, Sitas F, Newell DC, et al. Geographic association of Helicobacter pylori antibody prevalence and gastric cancer mortality in rural China. Int J Cancer 1990; 46:608-11.
90. Correa P, Fox J, Fontham E, et al. Helicobacter pylori and gastric carcinoma. Serum antibody prevalence in populations with contrasting cancer risks. Cancer 1990; 66:2569-74.
91. Nomura A, Stemmermann GN, Chyou P-H, Kalo I, Perez-Perez GI, Blaser MJ. Helicobacter pylori infection and gastric carcinoma among Japanese Americans in Hawaii. N Engl J Med 1991; 325:1132-6.
92. Parsonnet J, Friedman GD, Vandersteen DP, Chang Y, Vogelman JH, Orentreich N, Sibley RK. Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med 1991; 325:1127-31.
93. Forman D, Newell DG, Fullerton F, et al. Association between infection with Helicobacter pylori and risk of gastric cancer: evidence from a prospective study. Br Med J 1991; 302:1302-5.
94. Eurogast Study Group. An international association between Helicobacter pylori and gastric cancer. Lancet 1993; 341:1359-62.
95. Forman D. Helicobacter pylori infection and gastric carcinogenesis. Eur J Gastroenterol Hepatol 1992; 4(suppl 2):S31-5.
96. Forman D, Webb P, Parsonnet J. H. pylori and gastric cancer. Lancet 1994; 343:243-4.
97. Forman D, Webb PM. H. pylori and gastric cancer: the significance of the problem. In: Hunt RH, Tytgat GNJ, eds. Helicobacter pylori. Basic mechanisms to clinical cure. Dordrecht, Kluwer Academic Publishers, 1994.
98. Fox JG, Correa P, Taylor NS, et al. Campylobacter pylori-associated gastritis and immune response in a population at increased risk of gastric carcinoma. Am J Gastroenterol 1989; 84:775-81.
99. The Gastrointestinal Physiology Working Group. Helicobacter pylori and gastritis in Peruvian patients: relationship to socioeconomic level, age and sex. Am J Gastroenterol 1990; 85:819-23.
100. Megraud F. Epidemiology of Helicobacter pylori infection. Gastroenterol Clin N Am 1993; 22:73-88.
101. Graham D, Adam E, Reddy GT, et al. Seroepidemiology of Helicobacter infection in India. Comparison od developed and developing countries. Dig Dis Sci 1991; 36:1084-8.
102. Sitas F, Forman D, Yarnell JWG, et al. Helicobacter pylori infection rates in relation to age and social class in a population of Welsh men. Gut 1991; 32:25-8.
103. Barker DJP, Coggon D, Osmond C, Wickham C. Poor housing in childhood and high rates of stomach cancer in England and Wales. Br J Cancer 1990; 61:575-8.
104. Graham DY, Malaty HM, Evans DG, Evans DJ, Klein PD, Adam E. Epidemiology of Helicobacter pylori in an asymptomatic population in the United States. Effect of age, race and socioeconomic status. Gastroenterology 1991; 100:1495-501.
105. Muir CS, Waterhouse JW, Mack T, et al. Cancer incidence in five continents, vol.5. Lyon, International Agency for Research on Cancer, 1987.
106. Correa. P. Flaws in H. pylori-related carcinogenesis hypothesis. In: Hunt RH, Tytgat GNJ, eds. Helicobacter pylori. Basic mechanisms to clinical cure. Dordrecht, Kluwer Academic Publishers, 1994:523-8.
107. Farinati F, Valiante F, Germana B, et al. Prevalence of Helicobacter pylori infection in patients with precancerous changes and gastric cancer. Eur J Cancer Prev 1993; 1:321-6.
108. Banatvala N, Mayo K, Megraud F, Jennings R, Deeks JJ, Feldman RA. The cohort effect and Helicobacter pylori. J Infect Dis 1993; 168:219-21.
109. Kuipers EJ, Peña AS, van Kamp G, Uyterlinde AM, Pals C, Pels NFM, Kurz-Pohlman E, Meuwissen SGM. Seroconversion for Helicobacter pylori. Lancet 1993; 342:328-31.
110. Parsonnet J, Blaser MJ, Perez-Perez GI, et al. Symptoms and risk factors of Helicobacter pylori infection in a cohort of epidemiologists. Gastroenterology 1991; 102:41-6.
111. Sipponen P, Helske T, Järvinen P, Hyvärinen H, Seppälä K. Decrease in prevalence of chronic gastritis in a period of 15 years: analysis of outpatient series in Finland in 1977, 1985, 1992. Gut 1994; 35:000-000.
112. Sipponen P, Seppälä K. Long-term consequences of H. pylori infection: time trends in H. pylori gastritis, gastric cancer and peptic ulcer disease. In: Hunt RH, Tytgat GNJ, eds. Helicobacter pylori. Basic mechanisms to clinical cure. Kluwer Academic Publishers. Dordrecht/ Boston/ London, 1994, 372-80.
113. Lipkin M, Correa P, Mikol YB, et al. Proliferative and antigenic modifications in epithelial cells in chronic atrophic gastritis. J Natl Cancer Inst 1985; 75:613-19.
114. Lynch DAF, Mapstone NP, Clarke AMT, et al. Cell proliferation in Helicobacter pylori associated gastritis and the effect of eradication therapy. Gut 1995; 36:346-50.
115. Sobala GM, Crabtree JE, Dixon MF, et al. Acute Helicobacter pylori infection: clinical features, local systemic immune response, gastric mucosal histology and gastric juice ascorbic acid concentrations. Gut 1991; 32:1415-18.
116. Mirvish SS. Effects of vitamin C and E on N-nitroso-compound formation, carcinogenesis and cancer. Cancer 1986; 58 (suppl):1842-50.
117. Kyrtopoulos SA. Ascorbic acid and the formation of N-nitroso compounds: possible role of ascorbic acid in cancer prevention. Am J Clin Nutr 1987; 45:1344-50.
118. Sobala GM, Pignatelli B, Schorah CJ, et al. Simultaneous determination of ascorbic acid, nitrite, total nitrosocompounds and bile acids in fasting gastric juice, and gastric mucosal histology: implications for gastric carcinogenesis. Carcinogenesis 1991; 12:193-8.
119. Sobala GM, Schorah CJ, Shires S, et al. Effect of eradication of Helicobacter pylori on gastric juice ascorbic acid concentrations. Gut 1993; 34:1038-41.
120. Correa P, Cuello C, Gordillo G, et al. The gastric microenvironment in populations at high risk of stomach cancer. Natl Cancer Inst Monogr 1979; 53:167-70.
121. Schlag P, Bockler R, Peter M. Nitrite and nitrosamines in gastric juice: risk factors for gastric cancer? Scand J Gastroenterol 1982; 17:145-50.
122. Axon ATR. The ascorbic acid story. In: Hunt RH, Tytgat GNJ, eds. Helicobacter pylori. Basic mechanisms to clinical cure. Dordrecht, Kluwer Academic Publishers, 1994: 469-74.
123. Saito T, Inokuchi K, Takayama S, Sugimura T. Sequential morph-ological changes in N-methyl-N-nitro-N-nitrosoguanidine carcinogenesis in the glandular stomach of rats. J Natl Cancer Inst 1970; 44:769-83.
124. Scott N, Lansdown M, Diament R, et al. Helicobacter gastritis and intestinal metaplasia in a gastric cancer family. Lancet 1990; 335:728.
125. Correa P, Ruiz B. Campylobacter pylori and gastric cancer. In: Rathbone BJ, Heatley RV, eds. Campylobacter pylori and gastroduodenal disease. Oxford, Blackwell Scientific Publications, 1989:139-45.
126. Kuipers EJ, Perez-Perez GI, Meuwissen SGM, Blaser MJ. Helicobacter pylori and atrophic gastritis: Importance of the cagA status. J Natl Cancer Inst 1995; 87:1777-80.
127. Sakagami T, Dixon M, O'Rourke J, Hewlett R, Alderuccio F, Vella J, et al. Atrophic gastric changes in both Helicobacter felis and Helicobacter pylori infected mice are host dependent and separate from antral gastritis. Gut 1996; 39:639-48.
128. Borén T, Falk P, Roth KA, Larson G, Normark S. Attachment of H. pylori to human gastric epithelium mediated by blood group antigens. Science 1993; 262:1892-5.
129. Wersto RP, Liblit RL, Koss LG. Flow cytometric DNA analysis of human solid tumours: A review of the interpretation of DNA histograms. Hum Pathol 1991; 22:1085-00.
130. Carey FA, Lamb D, Bird CC. Intratumoral heterogeneity of DNA content in lung cancer. Cancer 1990; 65:2265-00.
131. Frierson HF. Flow cytometric analysis of ploidy in solid neoplasms: Comparison of fresh tissues with formalin-fixed paraffin-embedded specimens. Hum Pathol 1988; 19:290-00.
132. van Dam PA, Watson JV, Lowe DG, et al. Comparative evaluation of fresh, fixed, and cryopreserved solid tumour cells for reliable flow cytometry of DNA and tumour associated antigen. Cytometry 1992; 13:722-00.
133. Gilewski T, Norton L. Cytokinetics of neoplasia. In: Mendelsohn J, Howley PM, Israel MA, Liotta LA, eds. The molecular basis of cancer. London, WB Saunders, 1995:143-71.
134. Ballantyne KC, James PD, Robins RA, et al. Flow cytometric analysis of the DNA content of gastric cancer. Br J Cancer 1987; 56:82-4.
135. Wyatt JI, Quirke P, Ward DC, et al. Comparison of histopathological and flow cytometric parameters in prediction of prognosis in gastric cancer. J Pathol 1989; 158:195-201.
136. Nanus DM, Kelsen DP, Niedzwiecki D, et al. Flow cytometry as a predictive indicator in patients with operable gastric cancer. J Clin Oncol 1989; 8:1105-12.
137. Baretton G, Carstensen O, Schardey M, et al. DNA ploidy and survival in gastric carcinomas: A flow-cytometric study. Virchows Arch A 1991; 418:301-9.
138. Johnson H, Belluco C, Masood S, et al. The value of flow cytometric analysis in patients with gastric cancer. Arch Surg 1993; 128:314.
139. Petrova AS, Subrichina GN, Tschistjakova OV, et al. Flow cytofluorometry, cytomorphology and histology in gastric carcinoma. Oncology 1980; 37:318-24.
140. Sasaki K, Takahashi M, Hashimoto T, et al. Flow cytometric DNA measurement of gastric cancers. Clinicopathological implication of DNA ploidy. Pathol Res Pract 1989; 184:561-6.
141. Baba H, Korenaga D, Okamura T, et al. Prognostic significance of DNA content with special reference to age in gastric cancer. Cancer 1989; 63:1767-72.
142. Korenaga D, Haraguchi M, Okamura T, et al. DNA ploidy and tumour invasion in human gastric cancer. Histopathologic differentiation. Arch Surg 1989; 124:314-18.
143. YonemuraY, Ooyama S, Sugiyama K, et al. Retrospective analysing of the prognostic significance of DNA ploidy patterns and S-phase fraction in gastric carcinoma. Cancer Res 1990; 50:509-14.
144. Ferti-Passantonopoulou AD, Panani AD, Vlachos JD, et al. Common cytogenetic findings in gastric cancer. Cancer Genet Cytogenet 1987; 24:63-73.
145. Ochi H, Douglass HO, Sandberg AA. Cytogenetic studies in primary gastric cancer. Cancer Genet Cytogenet 1986; 22:295-307.
146. Rodriguez E, Rao PH, Ladanyi M, et al. 11p13-15 Is a specific region of chromosome rearrangement in gastric and esophageal adenocarcinomas. Cancer Res 1990; 50:6410-16.
147. Ochi H, Takeuch J, Douglass HO, et al. Trisomy X as a possible initial chromosome change in a gastric cancer. Cancer Genet Cytogenet 1984; 12:57-61.
148. Fey MF, Hesketh C, Wainscoat JS, et al. Clonal allelic loss in gastrointestinal cancers. Br J Cancer 1989; 59:750-4.
149. Wada M, Yokota J, Mizoguchi H, et al. Infrequent loss of chromosomal heterozygosity in human stomach cancer. Cancer Res 1988; 48:2988.
150. Sano T, Tsujino T, Yoshida K, et al. Frequent loss of heterozygosity on chromosomes 1q, 5q, and 17p in human gastric carcinomas. Cancer Res 1991; 51:2926.
151. Motomura K, Nishisho I, Takai S, et al. Loss of alleles at loci on chromosome 13 in human primary gastric cancers. Genomics 1988; 2:180-4.
152. Baffa R, Negrini M, Mandes B, et al. Loss of heterozygosity for chromosome 11 in adenocarcinoma of the stomach. Cancer Res 1996; 56: 268-72.
153. Yoshida K, Hamatani K, Koide H, Abe Y, Ikeda H, Tsuchiyama H, Nakayama E, Shiku H. Analysis of ras gene expression in stomach cancer by anti-ras p21 monoclonal antibodies. Cancer Defect Prev 1988; 12:369-76.
154. r 21 000 protein monoclonal antibodies and immunohistochemical analyses on expression of ras genes in human stomach and thyroid cancers. Cancer Res 1988; 48:5503-9.
155. Czerniak B, Herz F, Gorczyca W, Koss L. Expression of ras oncogene p21 protein in early gastric carcinoma and adjacent gastric epithelia. Cancer 1989; 64:1467-73.
156. Tahara E, Yasui W, Taniyama K, Ochiai A, Yamamoto T, Nakajo S, Yamamoto M. Ha-ras oncogene product in human gastric carcinoma: correlation with invasiveness, metastasis or prognosis. Jpn J Cancer Res 1986; 77:517-22.
157. Goyette M, Petropoulos CJ, Shank PR, Fausto N. Expression of a cellular oncogene during liver regeneration. Science 1983; 219:510-12.
158. Rodenhuis S. Ras and human tumours. Semin Cancer Biol 1992; 3:241-7.
159. Fujida K, Ohuchi N, Yao T, Okumura M, Fukushima Y, Kanakura Y, Kitamura Y, Fujita J. Frequent overexpression, but not activation by point mutation of ras genes in primary human gastric cancers. Gastroenterology 1987; 93:1339-45.
160. Deng G, Liu X, Wang J. Correlation of mutations of oncogene c-Ha-ras at codon 12 with metastases and survival of gastric cancer patients. Oncogene Res 1991; 6:33-8.
161. Kihana T, Tsuda H, Hirota T, Shimosato Y, Sakamoto H, Terada M, Hirohashi S. Point mutations of c-Ki-ras oncogene in gastric adenoma and adenocarcinoma with tubular differentiation. Jpn J Cancer Res 1991; 82: 308-14.
162. Lin SY, Chen PH, Wang CK, Liu JD, Siauw CP, Chen YJ, Yang MJ, Liu MH, Chen TC, Chang JG. Mutation analysis of K-ras oncogenes in gastroenterologic cancers by the amplified created restriction sites method. Am J Clin Path 1993; 100:686-9.
163. Jiang W, Kahn SM, Guillem JG, Lu SH, Weinstein IB. Rapid detection of ras oncogenes in human tumours: applications to colon, oesophageal and gastric cancer. Oncogene 1989; 4:923-8.
164. Victor T, Du Toit R, Jordaan AM, Bester AJ, van Helden PD. No evidence for point mutations in codons 12, 13, and 61 of the ras gene in a high incidence area for esophageal and gastric cancers. Cancer Res 1990; 50: 4911-14.
165. Nagata Y, Abe M, Kobayashi K, Yoshida K, Ishibashi T, Naoe T, Nakayama E, Shiku H. Glycine to aspartic acid mutations at codon 13 of the c-Ki-ras gene in human gastrointestinal cancers. Cancer Res 1990; 50:480-2.
166. Nanus DM, Kelsen DP, Mentle IR, Altorki N, Albino AP. Infrequent point mutations of ras oncogenes in gastric cancers. Gastroenterology 1990; 98:955-60.
167. Rodenhuis S, Slebos RJC. Clinical significance of ras oncogene activation in human lung cancer. Cancer Res 1992; 52:2665s-9s.
168. Suzuki Y, Orita M, Shiraishi M, Hayashi K, Sekiya N. Detection of ras gene mutation in human lung cancers by single-strand conformation polymorphism analysis of polymerase chain reaction products. Oncogene 1990; 5:1037-43.
169. Craanen ME, Blok P, Top B, Boerrigter L, Dekker W, Offerhaus GJA, Tytgat GNJ, Rodenhuis S. Absence of ras gene mutations in early gastric carcinomas. Gut 1995; 37:758-62.
170. Fukushige S, Matsubara K, Yoshida M, Sasaki M, Suzuki T, Semba K, Toyoshima K, Yamamoto T. Localization of a novel v-erbB-related gene, c-erbB-2, on human chromosome 17 and its amplification in a gastric cancer cell line. Mol Cell Biol 1986; 6:955-8.
171. Akiyama T, Sudo C, Ogawara H, Toyoshima K, Yamamoto T. The product of the human c-erbB-2 gene: a 185 kilodalton glycoprotein with tyrosine kinase activity. Science 1986; 232:1644-6.
172. Yamamoto T, Ikawa S, Akiyama T, Semba K, Nomura N, Miyajima N, Saito T, Toyoshima K. Similarity of protein encoded by the human c-erbB-2 gene to epidermal growth factor receptor. Nature 1986; 319:230-4.
173. Di Fiore PP, Pierce JH, Kraus MH, Segatto O, King CR, Aaronson SA. c-erbB-2 is a potent oncogene when overexpressed in NIH3T3 cells. Science 1987; 237:178-82.
174. D'Souza B, Berdichevsky F, Kyprianou N, Taylor-Papadimitriou J. Collagen-induced morphogenesis and expression of the alpha-2-integrin subunit is inhibited in c-erbB-2 transfected human mammary epithelial cells. Oncogene 1993; 8:1798-806.
175. D'Souza B, Taylor-Papadimitriou J. Overexpression of c-erbB-2 in human mammary epithelial cells signals inhibition of transcription of the e-cadherin gene. Proc Natl Acad Sci USA 1994; 91:7202-6.
176. Bouchard L, Lamarre L, Tremblay PJ, Jolicoeur P. Stochastic appearance of mammary tumours in transgenic mice carrying the mmtv/c-neu oncogene. Cell 1989; 57:931-6.
177. Tsuda H, Aizawa S, Furuta Y. Induction of a variety of tumours by c-erbB-2 and clonal nature of lymphomas with the mutated gene (Val659-Clu659). EMBO J 1990; 9:181-90.
178. Yu D, Wang S-S, Dulski KM, Tsai C-M, Nicolson GL, Hung M-C. c-erbB-2/neu Overexpression enhances metastatic potential of human lung cancer cells by induction of metastasis-associated properties. Cancer Res 1994; 54:3260-6.
179. Jain S, Filipe MI, Cullick WJ, Linehan J, Morris RW. c-erbB-2 Proto-oncogene expression and its relationship to survival in gastric carcinoma: an immunohistochemical study on archival material. Int J Cancer 1991; 48:668-71.
180. Jaehne J, Urmacher C, Thaler HT, Friedlander-Klar H, Cordon-Cardo C, Meyer HJ. Expression of Her2/neu oncogene product p185 in correlation to clinicopathological and prognostic factors of gastric carcinoma. J Cancer Res Clin Oncol 1992; 118:474-9.
181. Yonemura Y, Ninomiya I, Yamaguchi A, Fushida S, Kimura H, Ohoyama S, Miyazaki I, Endou Y, Tanaka M, Sasaki T. Evaluation of immunoreactivity for erbB-2 protein as a marker of poor short term prognosis in gastric cancer. Cancer Res 1991; 51:1034-8.
182. Hilton DA, West KP. c-erbB-2 Oncogene product expression and prognosis in gastric carcinoma. J Clin Pathol 1992; 45:454-6.
183. Falck VC, Cullick WJ. c-erbB-2 Oncogene product staining in gastric adenocarcinoma. An immunohistochemical study. J Pathol 1989; 159:107-11.
184. Press MF, Hung C, Godolphin W, Slamon DJ. Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. Cancer Res 1994; 54:2771-7.
185. Yokota J, Yamamoto T, Miyajima N, Tojoshima K, Nomura H, Sakamoto H, Yoshida T, Terada M, Sugimura T. Genetic alterations of the c-erbB-2 oncogene occur frequently in tubular adenocarcinoma of the stomach and are often accompanied by amplification of the v-erbA homologue. Oncogene 1988; 2:283-7.
186. Ranzani GN, Pellegata NS, Previdere C, Saragoni A, Vio A, Maltoni M, Amadori D. Heterogeneous proto-oncogene amplification correlates with tumour progression and presence of metastases in gastric cancer patients. Cancer Res 1990; 50:7811-14.
187. Blok P, Craanen ME, Dekker W, Offerhaus GJA, Tytgat GNJ. c-erbB-2 Overexpression in gastric carcinogenesis. Histopathology 1997; in press.
188. Meltzer PS. MDM2 and p53: a question of balance. J Natl Cancer Inst 1994; 86:1265-6.
189. Wu X, Bayle JH, Olson D, Levine A. The p53-MDM2 autoregulatory feedback loop. Genes and Development 1993; 7:1126-32.
190. Momand J, Zambetti GP, Olson DC, George D, Levine AJ. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992; 69:1237-45.
191. Finlay CA. The mdm-2 oncogene can overcome wild-type p53 suppression of transformed cell growth. Mol Cell Biol 1993; 13:301-6.
192. Fakharzadeh SS, Trusko SP, George DL. Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumour cell line. EMBO J 1991; 10:1565-9.
193. Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B. Amplification of a gene encoding a p53 associated protein in human sarcomas. Nature 1992; 358:80-3.
194. Oliner JD, Pietenpol JA, Thiagalingam S, Gyuris J, Kinzler KW, Vogelstein B. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature 1993; 362:857-60.
195. Leach FS, Tokino T, Meltzer P, Burrell M, Oliner JD, Smith S, Hill DE, Sidransky D, Kinzler K, Vogelstein B. p53 Mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res 1993; 53:2231-4.
196. Habuchi T, Kinoshita H, Yamada H, Kakehi Y, Ogawa O, Wu W-J, Takahashi R, Sugiyama T, Yoshida O. Oncogene amplification in urothelial cancers with p53 gene mutation or MDM2 amplification. J Natl Cancer Inst 1994; 86:1331-5.
197. Reifenberger G, Liu L, Ichimura K, Schmidt EE, Collins VP. Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res 1993; 53:2736-9.
198. Flørenes VA, Mælandsmo GM, Forus A, Andreassen Å, Myklebost O, Fodstad Ø. MDM2 gene amplification and transcript levels in human sarcomas: relationship to TP53 gene status. J Natl Cancer Inst 1994; 86: 1297-302.
199. Blok P, Craanen ME, Dekker W, Offerhaus GJA, Tytgat GNJ. No evidence for functional inactivation of wild-type p53 by MDM2 overexpression in gastric carcinogenesis. J Pathol 1997; submitted.
200. Cooper CS, Park M, Blair DG, et al. Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature 1984; 311:29-33.
201. Giordano S, Ponzetto C, Di Renzo MF, Cooper CS, Comoglio PM. Tyrosine kinase receptor indistinguishable from c-met protein. Nature 1989; 339:155-6.
202. Bottaro DP, Rubin JS, Faletto DL, et al. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 1991; 251:802-4.
203. Weidner KM, Behrens J, Vanderkerckhone J, Birchmaier W. Scatter factor: molecular characteristics and effect on the invasiveness of epithelial cells. J Cell Biol 1990; 111:2907-11.
204. Rong S, Segal S, Anver M, Resau JH, Vande Woude GF. Invasiveness and metastasis of NIH3T3 cells induced by met-hepatocyte growth factor/scatter factor autocrine stimulation. Proc Natl Acad Sci USA 1994; 91:4731-5.
205. Rong S, Bodescot M, Blair D, et al. Tumorigenicity of the met protooncogene and the gene for hepatocyte growth factor. Mol Cell Biol 1992; 12:5152-8.
206. Mondino A, Giordano S, Comoglio PM. Defective posttranslational processing activates the tyrosine kinase encoded by the met rotooncogene (hepatocyte growth factor receptor). Mol Cell Biol 1991; 11:6084-92.
207. Park M, Dean M, Cooper CS, et al. Mechanisms of met oncogene activation. Cell 1986; 45:895-904.
208. Kuniyasu H, Yasui W, Kitadai Y, Yokozaki H, Ito H, Tahara E. Frequent amplification of the c-met gene in scirrhous type stomach cancer. Biochem Biophys Res Commun 1992; 189:227-32.
209. Kuniyasu H, Yasui W, Yokozaki H, Kitadai Y, Tahara E. Aberrant expression of c-met mRNA in human gastric carcinomas. Int J Cancer 1993; 55:72-5.
210. Di Renzo MF, Narsimhan R, Olivero M, et al. Expression of the Met/HGF receptor in normal and neoplastic human tissues. Oncogene 1991; 6:1997-2003.
211. Soman NR, Correa P, Ruiz BA, Wogan GN. The TPR-MET oncogenic rearrangement is present and expressed in human gastric carcinoma and precursor lesions. Proc Natl Acad Sci USA 1991; 88:4892-6.
212. Gutman M, Ravia Y, Assaf D, et al. Amplification of c-myc and c-erbB-2 protooncogenes in human solid tumours: Frequency and clinical significance. Int J Cancer 1989; 44:802-5.
213. Shibuya M, Yokota J, Ueyama Y. Amplification and expression of a cellular oncogene (c-myc) in human gastric adenocarcinoma cells. Mol Cell Biol 1985; 5:414-18.
214. Tsuboi K, Hirayoshi K, Takeuchi K, et al. Expression of the c-myc gene in human gastrointestinal malignancies. Biochem Biophys Res Commun 1987; 146:699-704.
215. Yamamoto T, Yasui W, Ochiai A, et al. Immunohistochemical detection of c-myc oncogene product in human gastric carcinomas: expression in tumour cells and stromal cells. Jpn J Cancer Res 1987; 78: 1169-74.
216. Ciclitira PJ, Macartney JC, Evan G. Expression of c-myc in nonmalignant and premalignant gastrointestinal disorders. J Pathol 1987; 151:293-6.
217. Nakatani H, Sakamoto H, Yoshida T, et al. Isolation of an amplified DNA sequence in stomach cancer. Jpn J Cancer Res 1990; 81:707-10.
218. Nakatani H, Tahara E, Yoshida T, et al. Detection of amplified DNA sequences in gastric cancers by a DNA renaturation method in gel. Jpn J Cancer Res 1986; 77:849-53.
219. Sakamoto H, Mori M, Taira M, et al. Transforming gene from human stomach cancers and a noncancerous portion of stomach mucosa. Proc Natl Acad Sci USA 1986; 83:3997-4001.
220. Yoshida MC, Wada M, Satoh H, et al. Human HSJ1 (HSTF1) gene maps to chromosome band 11q13 and coamplifies with the INT2 gene in human cancer. Proc Natl Acad Sci USA 1988; 85:4861-4.
221. Tsuda T, Tahara E, Kajiyama G, et al. High incidence of coamplification of hst-1 and int-2 genes in human esophageal carcinomas. Cancer Res 1989; 49:5505-8.
222. Vogelstein B, Kinzler KW. p53 Function and dysfunction. Cell 1992; 70:523-6.
223. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B. WAF1, a potential mediator of p53 tumour suppression. Cell 1993; 75:817-25.
224. Davidoff AM, Humphrey PA, Iglehart JD, Marks JR. Genetic basis for p53 overexpression in human breast cancer. Proc Natl Acad Sci USA 1991; 88: 5006-10.
225. Marks JR, Davidoff AM, Kerns BJ, Humphrey PA, Pence JC, Dodge RK, Clarke-Pearson DL, Iglehart JD, Bast RC, Berchuck A. Overexpression and mutation of p53 in epithelial ovarian cancer. Cancer Res 1991; 51:2979-84.
226. Iggo R, Gatter K, Bartek J, Lane D, Harris AL. Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet 1990; 335: 675-9.
227. Imazeki F, Omata M, Nose H, Ohto M, Isono K. p53 Gene mutations in gastric and esophageal cancers. Gastroenterology 1992; 103:892-6.
228. Tamura G, Kihana T, Nomura K, Terada M, Sugimura T, Hirohashi S. Detection of frequent p53 gene mutations in primary gastric cancer by cell sorting and polymerase chain reaction single-strand conformation polymorphism analysis. Cancer Res 1991; 51:3056-8.
229. Yamada Y, Yoshida T, Hayashi K, Sekiya T, Yokota J, Hirohashi S, Nakatani K, Nakano H, Sugimura T, Terada M. p53 Gene mutations in gastric cancer metastases and in gastric cancer cell lines derived from metastases. Cancer Res 1991; 51:5800-5.
230. Renault B, van den Broek M, Fodde R, Wijnen J, Pellegata NS, Amadori D, et al. Base transitions most frequent genetic changes at p53 in gastric cancer. Cancer Res 1993; 53:2614-17.
231. Matozaki K, Sakamoto C, Suzuki T, Matsuda K, Uchida T, Nakano O, et al. p53 Gene mutations in human gastric cancer: Wild-type p53 but not mutant p53 suppresses growth of human gastric cancer cells. Cancer Res 1992; 52:4335-41.
232. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 Mutations in human cancer. Science 1991; 253:49-53.
233. Rugge M, Shiao YH, Correa P, Baffa R, Dimario F. Immunohisto-chemical evidence of p53 overexpresssion in gastric epithelial dysplasia. Cancer Epidem Biomarker Prev 1992; 1:551-4.
234. Joypaul BV, Newman EL, Hopwood D, Grant A, Qureshi S, Lane DP, Cuschieri A. Expression of p53 protein in normal, dysplastic, and malignant gastric mucosa: an immunohistochemical study. J Pathol 1993; 170:279-83.
235. Lauwers GY, Wahl SJ, Melamed J, Rojascorona RR. p53 Expression in precancerous gastric lesions - an immunohistochemical study of Pab 1801 monoclonal antibody on adenomatous and hyperplastic gastric polyps. Am J Gastroenterol 1993; 88:1916-19.
236. Craanen ME, Blok P, Dekker W, Offerhaus GJA, Tytgat GNJ. Chronology of p53 protein accumulation in gastric carcinogenesis. Gut 1995; 36:848-52.
237. Shiao Y-H, Rugge M, Correa P, Lehmann HP, Scheer WD. p53 Alteration in gastric precancerous lesions. Am J Pathol 1994; 144:511-17.
238. Martin HM, Filipe MI, Morris RW, Lane DL, Silvestre F. p53 Expression and prognosis in gastric carcinoma. Int J Cancer 1992; 50:859-62.
239. Kakeji Y, Korenaga D, Tsujitani S, Baba H, Anai H, Maehara Y, Sugimachi K. Gastric cancer with p53 overexpression has high potential for metastasising to lymph nodes. Br J Cancer 1993; 67:589-93.
240. Starzynska T, Bromley M, Ghosh A, Stern PL. Prognostic significance of p53 overexpression in gastric and colorectal carcinoma. Br J Cancer 1992; 66: 558-62.
241. Neumann WL, Wasylyshyn ML, Jacoby R, et al. Evidence for a common molecular pathogenesis in colorectal, gastric and pancreatic cancer. Genes Chromosom Cancer 1991; 3:468-73.
242. Rhyu M-G, Park W-S, Jung Y-J, Choi S-W, Meltzer SJ. Allelic deletions of MCC/APC and p53 are frequent late events in human gastric carcinogenesis. Gastroenterology 1994; 106:1584-8.
243. Horii A, Nakatsuru S, Miyoshi Y, et al. The APC gene, responsible for familial adenomatous polyposis, is mutated in human gastric cancer. Cancer Res 1992; 52:3231-3.
244. Nakatsuru S, Yanagisawa A, Ichii S, et al. Somatic mutation of the APC gene in gastric cancer: frequent mutations in very well differentiated adenocarcinoma and signet-ring cell carcinoma. Hum Mol Genet 1992; 8: 559-63.
245. Tamura G, Maesawa C, Suzuki Y, et al. Mutations of the APC gene occur during early stages of gastric adenoma development. Cancer Res 1992; 54:1149-51.
246. Cho KR, Fearon ER. DCC: Linking tumour suppressor genes and altered cell surface interactions in cancer? Eur J Cancer 1995; 31A:1055-00.
247. Uchino S, Tsuda H, Noguchi M, et al. Frequent loss of heterozygosity at the DCC locus in gastric cancer. Cancer Res 1992; 52:3099-102.
248. Leach FS, Nicolaides NC, Papadopoulos N, et al. Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer. Cell 1993; 75:1215-25.
249. Fishel R, Lescoe MK, Rao MRS, et al. The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colorectal cancer. Cell 1993; 75:1027-38.
250. Papadopoulos N, Nicolaides NC, Wei Y-F, et al. Mutation of a mutL homolog in hereditary colon cancer. Science 1994; 263:1625-9.
251. Bronner CE, Baker SM, Morrison PT, et al. Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary non-polyposis colon cancer. Nature 1994; 368:258-61.
252. Nicolaides NC, Papadopoulos N, Liu B, et al. Mutations of two PMS homologues in hereditary nonpolyposis colon cancer. Nature 1994; 371:75-80.
253. Thibodeau SN, Bren C, Schaid D. Microsatellite instability in cancer of the proximal colon. Science 1993; 260:816-19.
254. Ionov Y, Peinado MA, Malkhosyan S, Shibata D, Perucho M. Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature 1993; 363:558-61.
255. Rhyu M-G, Park W-S, Meltzer SJ. Microsatellite instability occurs frequently in human gastric carcinoma. Oncogene 1994; 9:29-32.
256. n repeats and tumour suppressor genes in human gastric cancer. Cancer Res 1994; 54:41-4.
257. Chong J-M, Fukayama M, Hayashi Y, Takizawa T, Koike M, Konishi M. Microsatellite instability in the progression of gastric carcinoma. Cancer Res 1994; 54:4595-7.
258. Strickler JG, Zheng J, Shu Q, et al. p53 Mutations and microsatellite instability in sporadic gastric cancer: when guardians fail. Cancer Res 1994; 54:4750-5.
259. Man H-J, Yanagisawa A, Kato Y, Park J-G, Nakamura Y. Genetic instability in pancreatic cancer and poorly differentiated type of gastric cancer. Cancer Res 1994; 54:41-4.
260. Tamura G, Sakata K, Maesawa C, et al. Microsatellite alterations in adenomas and differentiated adenocarcinoma of the stomach. Cancer Res 1995; 55:1933-6.
261. Dos Santos NR, Seruca R, Constância M, et al. Microsatellite instability at multiple loci in gastric carcinoma: clinicopathologic implications and prognosis. Gastroenterology 1996; 110:38-44.